|1.||Cole, Alexander M: 4 articles (01/2011 - 11/2004)|
|2.||Waring, Alan J: 3 articles (12/2007 - 11/2004)|
|3.||Lehrer, Robert I: 3 articles (12/2007 - 11/2004)|
|4.||Gupta, Phalguni: 2 articles (01/2011 - 05/2007)|
|5.||Cole, Amy L: 2 articles (12/2007 - 05/2007)|
|6.||Bacigalupo, Andrea: 1 article (08/2014)|
|7.||Orazi, Attilio: 1 article (08/2014)|
|8.||Andreasson, Bjorn: 1 article (08/2014)|
|9.||Weinberg, Rona S: 1 article (08/2014)|
|10.||Shore, Tsiporah B: 1 article (08/2014)|
12/01/2007 - "Overall, these data suggest that most mutations capable of rendering HIV-1 resistant to RC-101 will also exert deleterious effects on the ability of HIV-1 to initiate infections - an interesting and novel property for a potential topical microbicide."
05/01/2007 - "Collectively, these data support the potential development of RC-101 as a topical microbicide to prevent HIV-1 infection and transmission."
05/01/2007 - "The current study shows that RC-101, an analogue of retrocyclin, prevented HIV-1 infection in an organ-like construct of human cervicovaginal tissue and retained full activity in the presence of vaginal fluid. "
05/01/2007 - "The retrocyclin analogue RC-101 prevents human immunodeficiency virus type 1 infection of a model human cervicovaginal tissue construct."
12/01/2007 - "Retrocyclin RC-101, a theta-defensin with lectin-like properties, potently inhibits infection by many HIV-1 subtypes by binding to the heptad repeat 2 (HR2) region of glycoprotein 41 (gp41) and preventing six-helix bundle formation. "
12/01/2012 - "These dual properties, toxin inhibition and biofilm retardation, justify further exploration of RC-101 as a candidate agent for bacterial vaginosis prevention."
01/01/2011 - "Additionally, the effect of HVF on formulated RC-101 was evaluated with fluids collected from healthy volunteers, or from subjects with bacterial vaginosis (BV). "
|3.||Primary Myelofibrosis (Myelosclerosis)
|1.||Hematopoietic Stem Cell Transplantation